选择性COX-2抑制剂引起心血管风险的研究进展  

Research progress on cardiovascular risks induced by selective COX-2 inhibitors

作　　者：黄勇[1] 李頔[1] 王娜[1] 冉娅娟 雷筱梅(综述) 钱妍(审校)[1] HUANG Yong;LI Di;WANG Na;RAN Yajuan;LEI Xiaomei;QIAN Yan(Department of Pharmacy,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第二医院药学部,重庆400010

出　　处：《西南医科大学学报》2024年第1期87-92,共6页Journal of Southwest Medical University

基　　金：重庆市卫生适宜技术推广项目(2022jstg022)。

摘　　要：非甾体抗炎药(non-steroid anti-inflammatory drugs,NSAIDs)是一种有效的、广泛使用的抗炎镇痛药物,其对环氧合酶(cyclo-oxygenase,COX)亚型(COX-1、COX-2)的抑制作用将引起不同的反应,选择性COX-2抑制剂将显著增加不良心血管事件的风险,随着此类药物使用的增加和临床循证证据的积累,其带来的心血管风险引起了越来越多学者的关注。笔者通过归纳分析最新发表文献对选择性COX-2抑制剂引起心血管风险的研究进行综述,以期辅助临床合理用药,减少不良反应,提高用药安全性。Non-steroidal anti-inflammatory drugs(NSAIDs)are effective and widely used anti-inflammatory and analgesic drugs,and their inhibitory effects on cyclooxygenase(COX)will cause different reactions.Selective COX-2 inhibitors will significantly increase the risk of adverse cardiovascular events.With the increasing use of such drugs and the accumulation of clinical evidence,the cardiovascular risks they bring have attracted more and more attention from scholars.This review highlighted resent research of cardio⁃vascular risks caused by selective COX-2 inhibitors and provided evidences for rational drug use in clinical practice.

关 键 词：非甾体类抗炎药 环氧合酶 选择性环氧合酶-2抑制剂 心血管风险 

分 类 号：R969[医药卫生—药理学]